The firm is a global venture capital firm headquartered in Asia, with investment activity spanning Asia and the United States. The firm has raised multiple funds and recently launched a dedicated vehicle focused on biotechnology and medical technology innovation. The firm invests from Seed through early-growth stages and has backed a broad portfolio of healthcare companies. The firm deploys equity capital and works closely with founders to support global expansion, leveraging cross-border operating presence and networks across Asia and North America.
The firm focuses on biotechnology, medical technology, and enabling platforms addressing major unmet needs in human health. The firm invests in breakthrough science and engineering-driven innovation, including therapeutics, medtech devices, diagnostics, digital health, research tools, and frontier health technologies. The firm follows a cross-border strategy that sources scientific breakthroughs from both Eastern and Western ecosystems, particularly opportunities facing market fragmentation or structural barriers that may limit global scale. The firm emphasizes companies with strong scientific foundations, differentiated clinical or technical positioning, and opportunities that can benefit from accelerated development and market access through Asian clinical, talent, and supply chain ecosystems.
From a company and management team perspective, the firm partners with founders who demonstrate deep scientific or medical expertise, strong execution capability, and readiness for global expansion. The firm actively supports teams through hands-on venture building and provides access to clinical resources, supply networks, operating talent, and cross-border strategic guidance. The firm collaborates with companies from early stages through exit, aligning with founders to pursue global outcomes including IPOs, M&A, and strategic partnerships.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment